Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FIBRONEER-ACT nerandomilast in non-IPF fibrosing interstitial lung disease at risk of progression
NL-OMON61760Phase 3Not yet recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in pulmonary fibrosis (PF) and interstitial lung disease (ILD) comparing Nerandomilast with Placebo (2 arms). Primary endpoint: Absolute change from baseline in forced vital capacity. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
nerandomilast
03
Conditions
pulmonary fibrosis (PF)interstitial lung disease (ILD)
Beyond the preview
Go deeper on NL-OMON61760.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61760.